CX-659S

CX-659S is an orally active and novel derivative of 5-carboxamide uracil. CX-659S can effectively inhibit lipid peroxidation (IC50 = 5.9 μM) . CX-659S can reduce the infiltration of neutrophils and eosinophils. CX-659S inhibits the mRNA expression of pro-inflammatory cytokines IL-1β and TNF-α. CX-659S can be used for research on inflammatory conditions[1].

Product Specifications

CAS Number

[204980-81-4]

UNSPSC

12352005

Target

Interleukin Related; TNF Receptor

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

CC1=C2C(CC[C@](C)(O2)C(NC3=C(N(C4=CC=CC=C4)C(N(C3=O)C)=O)N)=O)=C(C(O)=C1C)C

Molecular Formula

C25H28N4O5

Molecular Weight

464.51

References & Citations

[1]Tobe M, et al. Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction. Bioorg Med Chem. 2000 Aug;8 (8) :2037-47. |[2]Goto Y, et al. Suppressive effect of topically applied CX-659S, a novel diaminouracil derivative, on the contact hypersensitivity reaction in various animal models. Int Arch Allergy Immunol. 2000 Dec;123 (4) :341-8.